Join patients and experts for a day of learning and connecting Register Free Today
Working to make a difference in the lives of all affected by cancer.
Learn About Our Work
Explore immunotherapy discoveries, treatment approvals and milestones.
See Our Breakthroughs
Learn more about this revolutionary cancer treatment.
Understand the Basics
Find clinical trials that match your diagnosis, stage and treatment history.
Meet the CRI scientists committed to the development of immunotherapy.
Two weeks ago, we reported that pembrolizumab worked well as first-line treatment for advanced lung cancer patients. Those benefits―which included a 40% reduction in risk of death compared to chemotherapy―led the FDA to grant Breakthrough Therapy Designation and Priority Review to the therapy.
Although the FDA had until December 24 to make a decision, U.S. regulators decided yesterday, two months ahead of schedule, to approve pembrolizumab (Keytruda ®, Merck) as a first-line option for patients with advanced non-small cell lung carcinoma (NSCLC). It’s important to note, however, that this approval is for patients whose tumors have high PD-L1 expression (more than half the cells expressed it) and don’t have any mutations in EGFR or ALK. Pembrolizumab is an anti-PD-1 checkpoint antibody that targets the PD-1/PD-L1 pathway and can help keep immune cells active against cancer.
FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer
Read Previous Article
CNN Highlights Cancer Immunotherapy Advances, CRI’s Pioneering Role
Read Next Article
*Immunotherapy results may vary from patient to patient.
National Headquarters | One Exchange Plaza
55 Broadway, Suite 1802 | New York, NY 10006
(800) 992-2623(212) 832-9376Staff Directory
Top immunotherapy experts from both academia and industry will convene for the 2nd annual Rational Combinations 360° conference, which will be held on June 28-29 at the New York Academy of Medicine.
The future of immunotherapy is in finding the right combinations